RecruitingPhase 1 / Phase 2NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Sponsor: Verastem, Inc.
Nashville, TN · +12 more sites
Colorectal Cancer clinical trials in Nashville, TN
49 recruiting colorectal cancer studies with a site in Nashville, TN.
RecruitingPhase 1 / Phase 2NCT05786924
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Sponsor: Institut de Recherches Internationales Servier
Nashville, TN · +20 more sites
RecruitingPhase 2NCT07023289
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Sponsor: AbbVie
Nashville, TN · +21 more sites
RecruitingPhase 3NCT07222800
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Sponsor: Pfizer
Nashville, TN · +253 more sites
RecruitingPhase 1 / Phase 2NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Sponsor: Parabilis Medicines, Inc.
Nashville, TN · +29 more sites
RecruitingPhase 1NCT04429542
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Sponsor: Bicara Therapeutics
Nashville, TN · +14 more sites
RecruitingPhase 1NCT07544589
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Sponsor: Dispatch Biotherapeutics
Nashville, TN · +6 more sites
RecruitingPhase 2NCT05673148
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Sponsor: Alliance for Clinical Trials in Oncology
Memphis, TN · Nashville, TN · +186 more sites
RecruitingPhase 1NCT06270706
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Sponsor: Pliant Therapeutics, Inc.
Nashville, TN · +15 more sites
RecruitingPhase 2NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Sponsor: Bayer
Nashville, TN · +10 more sites
RecruitingPhase 1NCT05877599
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Sponsor: AstraZeneca
Nashville, TN · +19 more sites
RecruitingPhase 1NCT06004245
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Sponsor: Vividion Therapeutics, Inc.
Nashville, TN · +15 more sites
RecruitingPhase 1NCT06218914
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Sponsor: AstraZeneca
Nashville, TN · +17 more sites
RecruitingPhase not listedNCT07124000
DESTINY-PANTUMOUR04
Sponsor: AstraZeneca
Nashville, TN · +17 more sites
RecruitingPhase 1NCT07277270
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Sponsor: GlaxoSmithKline
Nashville, TN · +4 more sites
RecruitingPhase 3NCT05863195
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Sponsor: ECOG-ACRIN Cancer Research Group
Nashville, TN · +61 more sites
RecruitingPhase 1 / Phase 2NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Sponsor: Neonc Technologies, Inc.
Nashville, TN · +7 more sites
RecruitingPhase 2NCT05489211
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Sponsor: AstraZeneca
Nashville, TN · +16 more sites
RecruitingPhase 1 / Phase 2NCT06445062
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Sponsor: Revolution Medicines, Inc.
Nashville, TN · +31 more sites
RecruitingPhase 1 / Phase 2NCT07629960
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Sponsor: Blueprint Medicines Corporation
Nashville, TN · +9 more sites
RecruitingPhase 1 / Phase 2NCT07213609
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Sponsor: GlaxoSmithKline
Nashville, TN · +3 more sites
RecruitingPhase 1NCT07217171
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Sponsor: EvolveImmune United, Inc
Nashville, TN · +14 more sites
RecruitingPhase 1NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Sponsor: Angiex, Inc.
Nashville, TN · +6 more sites
RecruitingPhase 3NCT06252649
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Sponsor: Amgen
Nashville, TN · +23 more sites
RecruitingPhase 1NCT06586515
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Sponsor: Eli Lilly and Company
Nashville, TN · +22 more sites
RecruitingPhase 2NCT06792695
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Sponsor: AstraZeneca
Nashville, TN · +13 more sites
RecruitingPhase 1 / Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Nashville, TN · +9 more sites
RecruitingPhase 1NCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Sponsor: ArriVent BioPharma, Inc.
Nashville, TN · +9 more sites
RecruitingPhase 1 / Phase 2NCT05592626
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
Nashville, TN · +12 more sites
RecruitingPhase 1 / Phase 2NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Sponsor: Daiichi Sankyo
Chattanooga, TN · Germantown, TN · Nashville, TN · +15 more sites
RecruitingPhase 1NCT05433142
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Sponsor: Xencor, Inc.
Nashville, TN · +19 more sites
RecruitingPhase 1 / Phase 2NCT05691491
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Sponsor: National Cancer Institute (NCI)
Nashville, TN · +22 more sites
RecruitingPhase 1 / Phase 2NCT04657068
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Sponsor: Artios Pharma Ltd
Chattanooga, TN · Memphis, TN · Nashville, TN · +38 more sites
RecruitingPhase 1 / Phase 2NCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Sponsor: Merus B.V.
Memphis, TN · Nashville, TN · +29 more sites
RecruitingPhase 1NCT06179160
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Sponsor: Incyte Corporation
Nashville, TN · +12 more sites
RecruitingPhase 1NCT06657144
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Sponsor: Coherus Oncology, Inc.
Nashville, TN · +19 more sites
RecruitingPhase 2NCT06937177
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Sponsor: Endevica Bio
Memphis, TN · Nashville, TN · +23 more sites
RecruitingPhase 2NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Sponsor: Jazz Pharmaceuticals
Knoxville, TN · Nashville, TN · +15 more sites
RecruitingPhase 1NCT04678648
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Sponsor: RasCal Therapeutics, Inc.
Nashville, TN · +2 more sites
RecruitingPhase 1NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Sponsor: IDEAYA Biosciences
Nashville, TN · +14 more sites
RecruitingPhase 1 / Phase 2NCT06051695
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Sponsor: A2 Biotherapeutics Inc.
Nashville, TN · +11 more sites
RecruitingPhase 1NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Sponsor: Context Therapeutics Inc.
Nashville, TN · +8 more sites
RecruitingPhase 1NCT06835569
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Sponsor: Alterome Therapeutics, Inc.
Nashville, TN · +11 more sites
RecruitingPhase 1 / Phase 2NCT03947385
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Sponsor: IDEAYA Biosciences
Nashville, TN · +11 more sites
RecruitingPhase 1 / Phase 2NCT05552755
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
Sponsor: Recursion Pharmaceuticals Inc.
Cordova, TN · Nashville, TN · +15 more sites
RecruitingPhase 1NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Nashville, TN · +15 more sites
RecruitingPhase 1 / Phase 2NCT05379985
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Sponsor: Revolution Medicines, Inc.
Chattanooga, TN · Nashville, TN · +19 more sites
RecruitingPhase 1 / Phase 2NCT06055439
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Sponsor: Chimeric Therapeutics
Nashville, TN · +3 more sites
Not yet recruitingPhase 1NCT07650357
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
Sponsor: Clasp Therapeutics, Inc.
Nashville, TN · +3 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.